Defining the viral PTMome: Towards the development of novel antiviral approaches

定义病毒 PTMome:致力于开发新型抗病毒方法

基本信息

  • 批准号:
    10261712
  • 负责人:
  • 金额:
    $ 112.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-30 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Over the past several decades, the traditional approach to combating viral infectious diseases has been to target the virus itself, in most cases by either blocking virus-encoded enzymes that are required for viral replication, or by preventing the virus from entering host cells. One of the major caveats of these approaches has been the ability of the virus to readily mutate and thereby become resistant to these classical types of antiviral therapies. In fact, this is a serious problem for the therapy of RNA virus infections, such as HIV or influenza virus, which are known to rapidly mutate and thereby escape antiviral drugs. Additionally, traditional antiviral approaches are designed to target a specific virus, and therefore are ineffective against any new virus that may emerge in the future, and it is impossible to predict what virus will cause the next outbreak or pandemic. Therefore, there is the urgent need to develop new ways for targeting viral pathogens, which will require creative and innovative research. Like human proteins, viral proteins robustly undergo posttranslational modifications (PTMs) for their regulation and proper functioning in the virus life cycle. In most cases, viral PTMs are dynamically regulated by human enzymes, such as kinases/phosphatases, ubiquitin E3 ligases/deubiquitinating enzymes, or acetyl transferases/deacetylases. Thus, cellular enzymes play an important role in controlling the ability of the virus to replicate and to cause disease. This proposal’s overarching goal is to comprehensively map the ‘viral PTMome’ to identify the PTMs that are essential for virus replication and pathogenesis. We will combine proteomics screens and molecular virology approaches including reverse genetics techniques with cutting- edge molecular, biochemical and biophysical studies. This will allow us to identify and characterize viral PTMs and the responsible host modifying enzymes, as well as to determine their roles for effective viral replication and pathogenesis. This powerful approach, combined with collaborative studies to design and test chemical inhibitors to block the enzymes that regulate critical viral PTMs, will not only provide unique mechanistic insight into host control of virus replication but will also lay the groundwork for developing new antivirals for a range of emerging viral infectious diseases.
项目摘要 在过去的几十年里,对抗病毒感染的传统方法 在大多数情况下,通过阻断病毒编码的 这些酶是病毒复制所需的,或者通过阻止病毒进入宿主细胞。 这些方法的一个主要警告是病毒容易变异的能力 从而变得对这些经典类型的抗病毒疗法有抗性。其实这是一个 RNA病毒感染如HIV或流感病毒的治疗存在严重问题, 这种病毒会迅速变异从而逃避抗病毒药物的治疗。此外,传统的抗病毒药物 这些方法被设计成针对特定的病毒,因此对任何新的病毒都是无效的。 未来可能出现的病毒,无法预测下一个病毒会导致什么 爆发或流行病。因此,迫切需要开发新的靶向病毒的方法 病原体,这将需要创造性和创新性的研究。 与人类蛋白质一样,病毒蛋白质也会经历翻译后修饰 (PTM)在病毒生命周期中的调节和正常功能。在大多数情况下, 由人类酶如激酶/磷酸酶、泛素E3 连接酶/去遍在蛋白酶,或乙酰基转移酶/去乙酰基酶。因此,细胞酶 在控制病毒复制和致病能力方面发挥重要作用。 该提案的总体目标是全面绘制“病毒PTMome”,以识别 对病毒复制和发病机制至关重要的PTM。我们将联合收割机蛋白质组学 筛选和分子病毒学方法,包括反向遗传学技术与切割- 边缘分子、生物化学和生物物理学研究。这将使我们能够识别和 表征病毒PTM和负责的宿主修饰酶,以及确定 它们在有效的病毒复制和发病机制中的作用。这种强大的方法,结合 合作研究,设计和测试化学抑制剂,以阻止调节 关键的病毒PTM,不仅将提供独特的机制洞察宿主控制病毒 复制,但也将为开发新的抗病毒药物奠定基础, 病毒性传染病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michaela Ulrike Gack其他文献

Michaela Ulrike Gack的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michaela Ulrike Gack', 18)}}的其他基金

Role of ADAM9 in viral RNA sensing and antiviral innate immunity
ADAM9 在病毒 RNA 传感和抗病毒先天免疫中的作用
  • 批准号:
    10753041
  • 财政年份:
    2023
  • 资助金额:
    $ 112.7万
  • 项目类别:
Defining the viral PTMome: Towards the development of novel antiviral approaches
定义病毒 PTMome:致力于开发新型抗病毒方法
  • 批准号:
    10490866
  • 财政年份:
    2021
  • 资助金额:
    $ 112.7万
  • 项目类别:
Defining the viral PTMome: Towards the development of novel antiviral approaches
定义病毒 PTMome:致力于开发新型抗病毒方法
  • 批准号:
    10662495
  • 财政年份:
    2021
  • 资助金额:
    $ 112.7万
  • 项目类别:
Novel Role for Host Immunostimulatory RNA in Antiviral Immune Defense
宿主免疫刺激 RNA 在抗病毒免疫防御中的新作用
  • 批准号:
    10338487
  • 财政年份:
    2021
  • 资助金额:
    $ 112.7万
  • 项目类别:
Novel Role for Host Immunostimulatory RNA in Antiviral Immune Defense
宿主免疫刺激 RNA 在抗病毒免疫防御中的新作用
  • 批准号:
    10492729
  • 财政年份:
    2021
  • 资助金额:
    $ 112.7万
  • 项目类别:
Novel Role for Host Immunostimulatory RNA in Antiviral Immune Defense
宿主免疫刺激 RNA 在抗病毒免疫防御中的新作用
  • 批准号:
    10676843
  • 财政年份:
    2021
  • 资助金额:
    $ 112.7万
  • 项目类别:
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
  • 批准号:
    10394983
  • 财政年份:
    2020
  • 资助金额:
    $ 112.7万
  • 项目类别:
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
  • 批准号:
    10623146
  • 财政年份:
    2020
  • 资助金额:
    $ 112.7万
  • 项目类别:
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
  • 批准号:
    10353335
  • 财政年份:
    2020
  • 资助金额:
    $ 112.7万
  • 项目类别:
EBV infection control by RNA surveillance
通过 RNA 监测控制 EBV 感染
  • 批准号:
    10283975
  • 财政年份:
    2019
  • 资助金额:
    $ 112.7万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 112.7万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 112.7万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 112.7万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 112.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 112.7万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 112.7万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 112.7万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 112.7万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 112.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 112.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了